Methodology breakdown computing — it will appear here on its own.
Alpha Cognition Inc. (ACOG) is currently considered not halal (non-compliant), per our secondary compliance provider (last assessed 2026-08-25). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computing the full ratio and business-activity breakdown for ACOG — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 47.30 | NEUTRAL |
| Stochastic %K (14) | 16.78 | BUY |
| CCI (20) | -77.46 | NEUTRAL |
| Williams %R (14) | -83.22 | BUY |
| MACD (12,26,9) | -0.10 | SELL |
| ROC (10) | -8.58 | SELL |
| Momentum (10) | -0.84 | SELL |
| EMA (10) | 9.18 | SELL |
| SMA (10) | 9.21 | SELL |
| EMA (20) | 9.15 | SELL |
| SMA (20) | 9.26 | SELL |
| EMA (30) | 9.00 | SELL |
| SMA (30) | 9.08 | SELL |
| EMA (50) | 8.62 | BUY |
| SMA (50) | 8.76 | BUY |
| EMA (100) | 7.90 | BUY |
| SMA (100) | 7.50 | BUY |
| EMA (200) | 7.25 | BUY |
| SMA (200) | 6.67 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.
Background via Yahoo Finance — informational, not part of the verdict.
Average — needs more confirmation before sizing up
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 43 |
| ⏰ 4H | BEARISH | 25 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | RANGING | 130 |
| ⏲ 5-Min | RANGING | 234 |
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-08 · Asset managers net 912361 (-21819)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.